PittsburghV1, France, Analysis, bibRecord, 000286

A proposal for an updated neuropsychopharmacological nomenclature.

Identifieur interne : 000286 ( France/Analysis ); précédent : 000285; suivant : 000287

A proposal for an updated neuropsychopharmacological nomenclature.

Auteurs : Joseph Zohar [Israël] ; David J. Nutt [Royaume-Uni] ; David J. Kupfer [États-Unis] ; Hans-Jurgen Moller [Allemagne] ; Shigeto Yamawaki [Japon] ; Michael Spedding [France] ; Stephen M. Stahl [Royaume-Uni]

Source :

European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology [ 1873-7862 ] ; 2014.

RBID : pubmed:24630385

Descripteurs français

KwdFr :
- Humains, Psychoanaleptiques (usage thérapeutique), Terminologie comme sujet, Troubles mentaux (traitement médicamenteux).
MESH :
- traitement médicamenteux : Troubles mentaux.
- usage thérapeutique : Psychoanaleptiques.
- Humains, Terminologie comme sujet.

English descriptors

KwdEn :
- Humans, Mental Disorders (drug therapy), Psychotropic Drugs (therapeutic use), Terminology as Topic.
MESH :
- chemical , therapeutic use : Psychotropic Drugs.
- drug therapy : Mental Disorders.
- Humans, Terminology as Topic.

Abstract

Current psychopharmacological nomenclature remains wedded in an earlier period of scientific understanding, failing to reflect contemporary developments and knowledge, does not aid clinicians in selecting the best medication for a given patient, and tends to confuse patients by prescribing a drug that does not reflect their identified diagnosis (e.g. prescribe "antipsychotics" to depression). Four major colleges of Neuropsychopharmacology (ECNP, ACNP, Asian CNP, and CINP) proposed a new template comprising a multi-axial pharmacologically-driven nomenclature tested by four surveys. The template has five axes: 1-class (primary pharmacological target and relevant mechanism); 2-family (reflecting the relevant neurotransmitter and mechanism); 3-neurobiological activities; 4-efficacy and major side effects; and 5-approved indications. The results of the surveys suggest that the clinicians found the available indication-based nomenclature system dissatisfactory, non-intuitive, confusing, and doubt-inducing for them and the patients. The proposed five-axis template seeks to upend current usage by placing pharmacology rather than indication as the primary axes, with the proposed nomenclature relating primarily to Axis 1-the class, and usage of the other axes would largely depend upon the extent to which the clinician seeks to deepen the scientific and clinical base of his involvement. A significant proportion of the participants in the four surveys were in favour of the proposed system, a similar number wanted to consider the idea further, and only a small proportion (8.6%) were against it. The proposed five-axis pharmacology based nomenclature template is a system which might refresh and reflect the current scientific concepts of neuropsychopharmacology.

DOI: 10.1016/j.euroneuro.2013.08.004
PubMed: 24630385

Affiliations:

Links to Exploration step

pubmed:24630385

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">A proposal for an updated neuropsychopharmacological nomenclature.</title>
<author><name sortKey="Zohar, Joseph" sort="Zohar, Joseph" uniqKey="Zohar J" first="Joseph" last="Zohar">Joseph Zohar</name>
<affiliation wicri:level="1"><nlm:affiliation>Department of Psychiatry, Sheba Medical Center, and Sackler School of Medicine, Tel Aviv University, Tel Hashomer, Israel. Electronic address: joseph.zohar@sheba.health.gov.il.</nlm:affiliation>
<country xml:lang="fr">Israël</country>
<wicri:regionArea>Department of Psychiatry, Sheba Medical Center, and Sackler School of Medicine, Tel Aviv University, Tel Hashomer</wicri:regionArea>
<wicri:noRegion>Tel Hashomer</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Nutt, David J" sort="Nutt, David J" uniqKey="Nutt D" first="David J" last="Nutt">David J. Nutt</name>
<affiliation wicri:level="3"><nlm:affiliation>Neuropsychopharmacology Unit, Division of Experimental Medicine, Imperial College London, London, United Kingdom.</nlm:affiliation>
<country xml:lang="fr">Royaume-Uni</country>
<wicri:regionArea>Neuropsychopharmacology Unit, Division of Experimental Medicine, Imperial College London, London</wicri:regionArea>
<placeName><settlement type="city">Londres</settlement>
<region type="country">Angleterre</region>
<region type="région" nuts="1">Grand Londres</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Kupfer, David J" sort="Kupfer, David J" uniqKey="Kupfer D" first="David J" last="Kupfer">David J. Kupfer</name>
<affiliation wicri:level="2"><nlm:affiliation>Department of Psychiatry, University of Pittsburgh School of Medicine and Western Psychiatric Institute and Clinic, Pittsburgh, PA, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Department of Psychiatry, University of Pittsburgh School of Medicine and Western Psychiatric Institute and Clinic, Pittsburgh, PA</wicri:regionArea>
<placeName><region type="state">Pennsylvanie</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Moller, Hans Jurgen" sort="Moller, Hans Jurgen" uniqKey="Moller H" first="Hans-Jurgen" last="Moller">Hans-Jurgen Moller</name>
<affiliation wicri:level="4"><nlm:affiliation>Department of Psychiatry and Psychotherapy, Ludwig-Maximilians-University, Munich, Germany.</nlm:affiliation>
<country xml:lang="fr">Allemagne</country>
<wicri:regionArea>Department of Psychiatry and Psychotherapy, Ludwig-Maximilians-University, Munich</wicri:regionArea>
<placeName><region type="land" nuts="1">Bavière</region>
<region type="district" nuts="2">District de Haute-Bavière</region>
<settlement type="city">Munich</settlement>
<settlement type="city">Munich</settlement>
</placeName>
<orgName type="university">Université Louis-et-Maximilien de Munich</orgName>
</affiliation>
</author>
<author><name sortKey="Yamawaki, Shigeto" sort="Yamawaki, Shigeto" uniqKey="Yamawaki S" first="Shigeto" last="Yamawaki">Shigeto Yamawaki</name>
<affiliation wicri:level="1"><nlm:affiliation>Department of Psychiatry and Neurosciences, Institute of Biomedical & Health Sciences, Hiroshima University, Hiroshima, Japan.</nlm:affiliation>
<country xml:lang="fr">Japon</country>
<wicri:regionArea>Department of Psychiatry and Neurosciences, Institute of Biomedical & Health Sciences, Hiroshima University, Hiroshima</wicri:regionArea>
<wicri:noRegion>Hiroshima</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Spedding, Michael" sort="Spedding, Michael" uniqKey="Spedding M" first="Michael" last="Spedding">Michael Spedding</name>
<affiliation wicri:level="1"><nlm:affiliation>Les laboratoires Servier, Suresnes, France.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>Les laboratoires Servier, Suresnes</wicri:regionArea>
<wicri:noRegion>Suresnes</wicri:noRegion>
<wicri:noRegion>Suresnes</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Stahl, Stephen M" sort="Stahl, Stephen M" uniqKey="Stahl S" first="Stephen M" last="Stahl">Stephen M. Stahl</name>
<affiliation wicri:level="4"><nlm:affiliation>Department of Psychiatry, University of California San Diego, San Diego, CA, USA; Department of Psychiatry, University of Cambridge, United Kingdom.</nlm:affiliation>
<country xml:lang="fr">Royaume-Uni</country>
<wicri:regionArea>Department of Psychiatry, University of California San Diego, San Diego, CA, USA; Department of Psychiatry, University of Cambridge</wicri:regionArea>
<placeName><settlement type="city">Cambridge</settlement>
<region type="country">Angleterre</region>
<region type="région" nuts="1">Angleterre de l'Est</region>
</placeName>
<orgName type="university">Université de Cambridge</orgName>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2014">2014</date>
<idno type="RBID">pubmed:24630385</idno>
<idno type="pmid">24630385</idno>
<idno type="doi">10.1016/j.euroneuro.2013.08.004</idno>
<idno type="wicri:Area/PubMed/Corpus">002557</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">002557</idno>
<idno type="wicri:Area/PubMed/Curation">002547</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">002547</idno>
<idno type="wicri:Area/PubMed/Checkpoint">002547</idno>
<idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">002547</idno>
<idno type="wicri:Area/Ncbi/Merge">001585</idno>
<idno type="wicri:Area/Ncbi/Curation">001585</idno>
<idno type="wicri:Area/Ncbi/Checkpoint">001585</idno>
<idno type="wicri:Area/Main/Merge">004469</idno>
<idno type="wicri:Area/Main/Curation">004247</idno>
<idno type="wicri:Area/Main/Exploration">004247</idno>
<idno type="wicri:Area/France/Extraction">000286</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">A proposal for an updated neuropsychopharmacological nomenclature.</title>
<author><name sortKey="Zohar, Joseph" sort="Zohar, Joseph" uniqKey="Zohar J" first="Joseph" last="Zohar">Joseph Zohar</name>
<affiliation wicri:level="1"><nlm:affiliation>Department of Psychiatry, Sheba Medical Center, and Sackler School of Medicine, Tel Aviv University, Tel Hashomer, Israel. Electronic address: joseph.zohar@sheba.health.gov.il.</nlm:affiliation>
<country xml:lang="fr">Israël</country>
<wicri:regionArea>Department of Psychiatry, Sheba Medical Center, and Sackler School of Medicine, Tel Aviv University, Tel Hashomer</wicri:regionArea>
<wicri:noRegion>Tel Hashomer</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Nutt, David J" sort="Nutt, David J" uniqKey="Nutt D" first="David J" last="Nutt">David J. Nutt</name>
<affiliation wicri:level="3"><nlm:affiliation>Neuropsychopharmacology Unit, Division of Experimental Medicine, Imperial College London, London, United Kingdom.</nlm:affiliation>
<country xml:lang="fr">Royaume-Uni</country>
<wicri:regionArea>Neuropsychopharmacology Unit, Division of Experimental Medicine, Imperial College London, London</wicri:regionArea>
<placeName><settlement type="city">Londres</settlement>
<region type="country">Angleterre</region>
<region type="région" nuts="1">Grand Londres</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Kupfer, David J" sort="Kupfer, David J" uniqKey="Kupfer D" first="David J" last="Kupfer">David J. Kupfer</name>
<affiliation wicri:level="2"><nlm:affiliation>Department of Psychiatry, University of Pittsburgh School of Medicine and Western Psychiatric Institute and Clinic, Pittsburgh, PA, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Department of Psychiatry, University of Pittsburgh School of Medicine and Western Psychiatric Institute and Clinic, Pittsburgh, PA</wicri:regionArea>
<placeName><region type="state">Pennsylvanie</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Moller, Hans Jurgen" sort="Moller, Hans Jurgen" uniqKey="Moller H" first="Hans-Jurgen" last="Moller">Hans-Jurgen Moller</name>
<affiliation wicri:level="4"><nlm:affiliation>Department of Psychiatry and Psychotherapy, Ludwig-Maximilians-University, Munich, Germany.</nlm:affiliation>
<country xml:lang="fr">Allemagne</country>
<wicri:regionArea>Department of Psychiatry and Psychotherapy, Ludwig-Maximilians-University, Munich</wicri:regionArea>
<placeName><region type="land" nuts="1">Bavière</region>
<region type="district" nuts="2">District de Haute-Bavière</region>
<settlement type="city">Munich</settlement>
<settlement type="city">Munich</settlement>
</placeName>
<orgName type="university">Université Louis-et-Maximilien de Munich</orgName>
</affiliation>
</author>
<author><name sortKey="Yamawaki, Shigeto" sort="Yamawaki, Shigeto" uniqKey="Yamawaki S" first="Shigeto" last="Yamawaki">Shigeto Yamawaki</name>
<affiliation wicri:level="1"><nlm:affiliation>Department of Psychiatry and Neurosciences, Institute of Biomedical & Health Sciences, Hiroshima University, Hiroshima, Japan.</nlm:affiliation>
<country xml:lang="fr">Japon</country>
<wicri:regionArea>Department of Psychiatry and Neurosciences, Institute of Biomedical & Health Sciences, Hiroshima University, Hiroshima</wicri:regionArea>
<wicri:noRegion>Hiroshima</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Spedding, Michael" sort="Spedding, Michael" uniqKey="Spedding M" first="Michael" last="Spedding">Michael Spedding</name>
<affiliation wicri:level="1"><nlm:affiliation>Les laboratoires Servier, Suresnes, France.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>Les laboratoires Servier, Suresnes</wicri:regionArea>
<wicri:noRegion>Suresnes</wicri:noRegion>
<wicri:noRegion>Suresnes</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Stahl, Stephen M" sort="Stahl, Stephen M" uniqKey="Stahl S" first="Stephen M" last="Stahl">Stephen M. Stahl</name>
<affiliation wicri:level="4"><nlm:affiliation>Department of Psychiatry, University of California San Diego, San Diego, CA, USA; Department of Psychiatry, University of Cambridge, United Kingdom.</nlm:affiliation>
<country xml:lang="fr">Royaume-Uni</country>
<wicri:regionArea>Department of Psychiatry, University of California San Diego, San Diego, CA, USA; Department of Psychiatry, University of Cambridge</wicri:regionArea>
<placeName><settlement type="city">Cambridge</settlement>
<region type="country">Angleterre</region>
<region type="région" nuts="1">Angleterre de l'Est</region>
</placeName>
<orgName type="university">Université de Cambridge</orgName>
</affiliation>
</author>
</analytic>
<series><title level="j">European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology</title>
<idno type="eISSN">1873-7862</idno>
<imprint><date when="2014" type="published">2014</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Humans</term>
<term>Mental Disorders (drug therapy)</term>
<term>Psychotropic Drugs (therapeutic use)</term>
<term>Terminology as Topic</term>
</keywords>
<keywords scheme="KwdFr" xml:lang="fr"><term>Humains</term>
<term>Psychoanaleptiques (usage thérapeutique)</term>
<term>Terminologie comme sujet</term>
<term>Troubles mentaux (traitement médicamenteux)</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Psychotropic Drugs</term>
</keywords>
<keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Mental Disorders</term>
</keywords>
<keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Troubles mentaux</term>
</keywords>
<keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr"><term>Psychoanaleptiques</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Humans</term>
<term>Terminology as Topic</term>
</keywords>
<keywords scheme="MESH" xml:lang="fr"><term>Humains</term>
<term>Terminologie comme sujet</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Current psychopharmacological nomenclature remains wedded in an earlier period of scientific understanding, failing to reflect contemporary developments and knowledge, does not aid clinicians in selecting the best medication for a given patient, and tends to confuse patients by prescribing a drug that does not reflect their identified diagnosis (e.g. prescribe "antipsychotics" to depression). Four major colleges of Neuropsychopharmacology (ECNP, ACNP, Asian CNP, and CINP) proposed a new template comprising a multi-axial pharmacologically-driven nomenclature tested by four surveys. The template has five axes: 1-class (primary pharmacological target and relevant mechanism); 2-family (reflecting the relevant neurotransmitter and mechanism); 3-neurobiological activities; 4-efficacy and major side effects; and 5-approved indications. The results of the surveys suggest that the clinicians found the available indication-based nomenclature system dissatisfactory, non-intuitive, confusing, and doubt-inducing for them and the patients. The proposed five-axis template seeks to upend current usage by placing pharmacology rather than indication as the primary axes, with the proposed nomenclature relating primarily to Axis 1-the class, and usage of the other axes would largely depend upon the extent to which the clinician seeks to deepen the scientific and clinical base of his involvement. A significant proportion of the participants in the four surveys were in favour of the proposed system, a similar number wanted to consider the idea further, and only a small proportion (8.6%) were against it. The proposed five-axis pharmacology based nomenclature template is a system which might refresh and reflect the current scientific concepts of neuropsychopharmacology.</div>
</front>
</TEI>
<affiliations><list><country><li>Allemagne</li>
<li>France</li>
<li>Israël</li>
<li>Japon</li>
<li>Royaume-Uni</li>
<li>États-Unis</li>
</country>
<region><li>Angleterre</li>
<li>Angleterre de l'Est</li>
<li>Bavière</li>
<li>District de Haute-Bavière</li>
<li>Grand Londres</li>
<li>Pennsylvanie</li>
</region>
<settlement><li>Cambridge</li>
<li>Londres</li>
<li>Munich</li>
</settlement>
<orgName><li>Université Louis-et-Maximilien de Munich</li>
<li>Université de Cambridge</li>
</orgName>
</list>
<tree><country name="Israël"><noRegion><name sortKey="Zohar, Joseph" sort="Zohar, Joseph" uniqKey="Zohar J" first="Joseph" last="Zohar">Joseph Zohar</name>
</noRegion>
</country>
<country name="Royaume-Uni"><region name="Angleterre"><name sortKey="Nutt, David J" sort="Nutt, David J" uniqKey="Nutt D" first="David J" last="Nutt">David J. Nutt</name>
</region>
<name sortKey="Stahl, Stephen M" sort="Stahl, Stephen M" uniqKey="Stahl S" first="Stephen M" last="Stahl">Stephen M. Stahl</name>
</country>
<country name="États-Unis"><region name="Pennsylvanie"><name sortKey="Kupfer, David J" sort="Kupfer, David J" uniqKey="Kupfer D" first="David J" last="Kupfer">David J. Kupfer</name>
</region>
</country>
<country name="Allemagne"><region name="Bavière"><name sortKey="Moller, Hans Jurgen" sort="Moller, Hans Jurgen" uniqKey="Moller H" first="Hans-Jurgen" last="Moller">Hans-Jurgen Moller</name>
</region>
</country>
<country name="Japon"><noRegion><name sortKey="Yamawaki, Shigeto" sort="Yamawaki, Shigeto" uniqKey="Yamawaki S" first="Shigeto" last="Yamawaki">Shigeto Yamawaki</name>
</noRegion>
</country>
<country name="France"><noRegion><name sortKey="Spedding, Michael" sort="Spedding, Michael" uniqKey="Spedding M" first="Michael" last="Spedding">Michael Spedding</name>
</noRegion>
</country>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Amérique/explor/PittsburghV1/Data/France/Analysis

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000286 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/France/Analysis/biblio.hfd -nk 000286 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Amérique
   |area=    PittsburghV1
   |flux=    France
   |étape=   Analysis
   |type=    RBID
   |clé=     pubmed:24630385
   |texte=   A proposal for an updated neuropsychopharmacological nomenclature.
}}

Pour générer des pages wiki

HfdIndexSelect -h $EXPLOR_AREA/Data/France/Analysis/RBID.i   -Sk "pubmed:24630385" \
       | HfdSelect -Kh $EXPLOR_AREA/Data/France/Analysis/biblio.hfd   \
       | NlmPubMed2Wicri -a PittsburghV1

This area was generated with Dilib version V0.6.38.
Data generation: Fri Jun 18 17:37:45 2021. Site generation: Fri Jun 18 18:15:47 2021

Serveur d'exploration sur Pittsburgh

A proposal for an updated neuropsychopharmacological nomenclature.

A proposal for an updated neuropsychopharmacological nomenclature.

Source :

Descripteurs français

English descriptors

Abstract

Links toward previous steps (curation, corpus...)

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri

Pour générer des pages wiki

	Serveur d'exploration sur Pittsburgh
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.